A Wealth Manager’s Discard: Bio-Techne and the Fickle Hand of Fortune

by

Now, listen here. A fella named Hollow Brook – a wealth manager, mind you, which is a fancy way of sayin’ a caretaker of other folks’ fortunes – recently up and dumped every last share of Bio-Techne. Every one. Like a bad penny, they tossed it. Happened back in the latter days of ’25, according to the official record books – those SEC filings, full of more numbers than a Mississippi steamboat gambler’s ledger. A tidy sum, some $10.7 million worth of shares went sailin’ out the door. Makes a body wonder what secrets they knew, don’t it?

A Bit More to the Tale

  • This Hollow Brook, they’re clean broke of Bio-Techne now. Not a single share remainin’ in their keepin’. Represents precisely zero percent of their holdings – a mighty decisive move, wouldn’t you say?
  • Their favorite treasures now? Gold, o’ course. $104 million worth, to be exact. Then some DMLP, MSFT, and GOOGL thrown in for good measure. Seems a body can’t go wrong bettin’ on shiny metal and those digital contraptions.
  • As of March the thirteenth of ’26, Bio-Techne shares were fetchin’ $51.47 apiece. Down a good twelve and two-thirds percent from where they were a year prior. A bit like a prize mule that’s lost its pep, wouldn’t you agree?

The Company Itself, Briefly

Metric Value
Revenue (TTM) $1.22 billion
Net Income (TTM) $81.10 million
Dividend Yield 0.62%
Price (as of Mar. 12, 2026) $51.47

What They Do, These Bio-Techne Folks

  • They manufacture and peddle life science reagents, instruments, and diagnostic doodads – proteins, antibodies, assays, the whole shebang.
  • They sell these wares to academic institutions, pharmaceutical companies, and anyone else with a laboratory and a pocketful of cash.
  • They serve the folks who poke and prod at life, tryin’ to understand it and, if they’re lucky, make a profit doin’ so.

Bio-Techne, you see, is one of those companies that provides the tools for other companies to do their work. A vital role, no doubt, but a precarious one. They rely on the success of others, and when those others stumble, well, Bio-Techne feels the pinch. They’re a respectable outfit, mind you, with a good position in the protein sciences and a diverse portfolio of brands. But respectability don’t always translate to profits, does it?

What This All Means for You, the Investor

Now, this Hollow Brook’s complete departure from Bio-Techne is a curious thing. A partial sale, you might shrug it off. But to unload everything? That sends a signal, like a distant train whistle in the night. It suggests they’ve lost faith, or perhaps they’ve simply found a shinier bauble to chase.

Bio-Techne has been havin’ a rough patch, truth be told. Shares have lagged behind the market by a considerable margin, weighed down by sluggish spendin’ from their biopharma and biotech customers. Revenue growth has slowed to a crawl, and their most recent quarter showed flat results. Not exactly the kind of momentum that inspires confidence, is it?

However, don’t go writin’ off Bio-Techne just yet. They still have some things goin’ for them. Roughly eighty percent of their revenue is recurring, which is a comfort. They hold a respected position in the protein sciences, and the average analyst price target is considerably higher than the current share price. And let’s not forget that Hollow Brook’s largest remaining holdin’ is a gold ETF. That tells you somethin’ about their risk tolerance – or lack thereof. They may simply be seekin’ safer harbors as the seas grow choppy.

In the end, it’s a gamble, like most things in this world. And a wise man knows when to hold ’em, when to fold ’em, and when to walk away from the table altogether.

Read More

2026-03-13 21:55